Renalytix Plc
RNLX · NASDAQ
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | $11 | $17 | $40 | $18 |
| - Cash | $1 | $5 | $5 | $6 |
| + Debt | $8 | $9 | $9 | $8 |
| Enterprise Value | $18 | $21 | $45 | $21 |
| Revenue | $1 | $1 | $1 | $1 |
| % Growth | -10.9% | 9.5% | -24.5% | – |
| Gross Profit | $0 | $0 | -$0 | $0 |
| % Margin | 19.2% | 6.1% | -12.3% | 32.3% |
| EBITDA | -$4 | -$5 | -$6 | -$9 |
| % Margin | -772.4% | -932.6% | -1,134% | -1,252.2% |
| Net Income | -$5 | -$7 | -$8 | -$8 |
| % Margin | -905.7% | -1,207.2% | -1,447.3% | -1,196.8% |
| EPS Diluted | -0.08 | -0.1 | -0.16 | -0.18 |
| % Growth | 20% | 37.5% | 11.1% | – |
| Operating Cash Flow | -$4 | -$8 | -$5 | -$8 |
| Capital Expenditures | $0 | -$0 | -$0 | $0 |
| Free Cash Flow | -$4 | -$8 | -$5 | -$8 |